{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"NE","upperLimit":"NE","value":"76"},{"groupId":"OG001","lowerLimit":"NE","upperLimit":"NE","value":"78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Percent of Participants Achieving Overall Combined Complete Response (CR) (CR w/normalized serum κ:λ ratio + CR + Near Complete Response (nCR)) following stem cell transplantation.\n\n* CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow.\n* κ:λ ratio: normal free light chain (FLC) ratio\n* nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow.","groups":[{"description":"bortezomib, dexamethasone, and thalidomide","id":"OG000","title":"Three Drug Regimen (VDT)"},{"description":"bortezomib, dexamethasone, thalidomide, and cyclophosphamide","id":"OG001","title":"Four Drug Regimen (VDTC)"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population is defined as all subjects who have measurable disease at baseline, receive at least 1 dose of any study drug and have at least 1 post-transplantation response assessment. The response-evaluable population comprises 38 subjects in the VDT treatment group and 27 subjects in the VDTC group.","reportingStatus":"POSTED","timeFrame":"all data included in clinical database as of 10 April 2009","title":"Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}